Summary of COVID-19 cenicriviroc studies

1. O’Halloran et al., Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia

723 patient cenicriviroc late treatment RCT: 30% higher mortality (p=0.15), 8% worse improvement (p=0.62), and 1% improved recovery (p=0.91).
RCT 723 hospitalized COVID-19 patients showing no significant difference in outcomes with cenicriviroc treatment.
Jul 2023, JAMA, https://jamanetwork.com/journals/jama/fullarticle/2807333, https://c19p.org/ohalloran

2. Files et al., Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial

261 patient cenicriviroc late treatment RCT: 24% higher mortality (p=0.28) and 14% worse recovery (p=0.46).
RCT 261 severe COVID-19 patients showing no significant difference in outcomes with cenicriviroc.
Mar 2023, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537023000664, https://c19p.org/filescvc

3. Kurth et al., Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial

30 patient cenicriviroc late treatment RCT: 500% higher need for oxygen therapy (p=0.26), 100% worse recovery (p=0.55), and 17% longer hospitalization (p=0.42).
RCT 30 hospitalized COVID-19 patients showing no significant difference in clinical improvement with cenicriviroc (CVC) treatment compared to placebo.
Mar 2023, J. Global Antimicrobial Resistance, https://www.sciencedirect.com/science/article/pii/S2213716522003630, https://c19p.org/kurth